Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The Danish Breast Cancer Cooperative Group (DBCG) wishes to clarify if recurrence-free and
overall life expectancy is longer after docetaxel and cyclophosphamide compared to epirubicin
and cyclophosphamide followed by docetaxel in patients with TOP2A normal and operable breast
cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Danish Breast Cancer Cooperative Group
Collaborators:
Dako Fonden Til Fremme af Klinisk- Eksperimentel Cancerforskning Sanofi